Feb 18 (Reuters) - Septerna Inc SEPN.O:
SEPTERNA ANNOUNCES DISCONTINUATION OF SEP-786 PHASE 1 CLINICAL TRIAL AND PLANS TO ADVANCE NEXT-GENERATION ORAL SMALL MOLECULE PTH1R AGONIST
SEPTERNA INC - DECISION FOLLOWS SEVERE EVENTS OF ELEVATED BILIRUBIN IN PHASE 1 TRIAL
SEPTERNA INC - NO LIVER INJURY OR SERIOUS ADVERSE EVENTS IN PHASE 1 TRIAL
SEPTERNA INC - EXPECTS CASH POSITION TO SUPPORT OPERATIONS INTO 2027
SEPTERNA INC: ADVANCING MULTIPLE NEXT-GENERATION PTH1R AGONISTS WITH DISTINCT AND UNRELATED CHEMICAL STRUCTURES RELATIVE TO SEP-786
Source text: ID:nGNXbKM318
Further company coverage: SEPN.O